The importance of appropriate antimicrobial dosing: Pharmacokinetic and pharmacodynamic considerations

被引:14
|
作者
Preston, SL [1 ]
机构
[1] Albany Med Coll, Clin Pharmacol Studies Unit, Albany, NY 12208 USA
关键词
D O I
10.1345/aph.1E218
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The increasing antimicrobial resistance of common respiratory pathogens has led to a reevaluation of the selection of antimicrobial dosing regimens in terms of their pharmacokinetic (PK) and pharmacodynamic (PD) properties. Pharmacokinetics, when considered as part of a specific dosing regimen, can help determine the time course of drug concentrations in the serum, tissues, body fluids, and at the site of infection. Pharmacodynamics provides surrogate markers for clinical and bacteriologic efficacy based on the relationships between the serum and tissue concentrations of selected antimicrobial agents relative to the mean inhibitory concentrations of causative bacteria over time. Ultimately, the interrelationships between PK and PD parameters measured for standard dosing regimens determine the time course of the drug's concentration at the site of infection and the impact of the agent's bacteriologic and clinical efficacy. In this review, the distinctive patterns of antimicrobial activity based on PK/PD parameters are discussed. Various antibiotics and bacterial pathogens are used as models to demonstrate the utility of PK/PD parameters in predicting the in vivo efficacy of antimicrobial therapy. The use of computer modeling with Monte Carlo population simulations can further enhance the predictability of antimicrobial efficacy when using PK/PD parameters. This article also provides a reevaluation of bacterial susceptibility breakpoints defined by the National Committee for Clinical Laboratory Standards contrasted with the use of PK/PD parameters.
引用
收藏
页码:S14 / S18
页数:5
相关论文
共 50 条
  • [1] Optimisation of Antimicrobial Dosing Based on Pharmacokinetic and Pharmacodynamic Principles
    Hoo, Grace Si Ru
    Liew, Yi Xin
    Kwa, Andrea Lay-Hoon
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2017, 35 (03) : 340 - 346
  • [2] Rational dosing of antimicrobial agents: Pharmacokinetic and pharmacodynamic strategies
    Owens, Robert C., Jr.
    Shorr, Andrew F.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (12) : S23 - S30
  • [3] Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis
    Fujii, Motoki
    Karumai, Toshiyuki
    Yamamoto, Ryohei
    Kobayashi, Eri
    Ogawa, Kenta
    Tounai, Mayuko
    Lipman, Jeffrey
    Hayashi, Yoshiro
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2020, 16 (05) : 415 - 430
  • [4] Antimicrobial Treatment of Febrile Neutropenia: Pharmacokinetic–Pharmacodynamic Considerations
    Tiphaine Goulenok
    Bruno Fantin
    Clinical Pharmacokinetics, 2013, 52 : 869 - 883
  • [5] Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin
    Drusano, G
    CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 : 24 - 29
  • [6] Sequential antimicrobial therapy: Pharmacokinetic and pharmacodynamic considerations in sequential therapy
    MacGowan, AP
    Bowker, KE
    JOURNAL OF INFECTION, 1998, 37 : 30 - 36
  • [7] Antimicrobial Treatment of Febrile Neutropenia: Pharmacokinetic-Pharmacodynamic Considerations
    Goulenok, Tiphaine
    Fantin, Bruno
    CLINICAL PHARMACOKINETICS, 2013, 52 (10) : 869 - 883
  • [8] Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill
    Tsai, Danny
    Lipman, Jeffrey
    Roberts, Jason A.
    CURRENT OPINION IN CRITICAL CARE, 2015, 21 (05) : 412 - 420
  • [9] Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19
    Leung, Elizabeth
    Crass, Ryan L.
    Jorgensen, Sarah C. J.
    Raybardhan, Sumit
    Langford, Bradley J.
    Moore, W. Justin
    Rhodes, Nathaniel J.
    CLINICAL PHARMACOKINETICS, 2022, 61 (02) : 155 - 165
  • [10] Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19
    Elizabeth Leung
    Ryan L. Crass
    Sarah C. J. Jorgensen
    Sumit Raybardhan
    Bradley J. Langford
    W. Justin Moore
    Nathaniel J. Rhodes
    Clinical Pharmacokinetics, 2022, 61 : 155 - 165